Nifurtimox

硝呋替莫

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameNifurtimox
Drug Alias Name硝蚨莫司Nifurtimox-eflornithine combination therapy硝呋莫司NECT硝呋噻氧 +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDNA damage modulators
TargetsNot applicable
Therapy Area/IndicationsCentral Nervous System NeoplasmsNeuroblastomaTrypanosomiasis, African +[4] 
Global Approved IndicationsTrypanosomiasis, AfricanChagas Disease
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved Date1965/01/01
Country/TerritoryUnited StatesArgentinaBolivia +[5] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBayer AG
China Registration ClassN/A

Develop Information

Active CompaniesBayer AGBayer Healthcare Pharmaceuticals IncBayer Healthcare Pharmaceuticals +[4] 
Inactive CompaniesUniversity Of Vermont
Active IndicationsCentral Nervous System NeoplasmsNeuroblastomaTrypanosomiasis, African +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeP01CC01
Related LinksWikipediaKEGG